Posted by Michael Wonder on 06 Mar 2018
FDA authorises, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes
6 March 2018 - Test only reports 3 out of more than 1,000 known BRCA mutations and negative result doesn’t rule out increased cancer risk.
The U.S. FDA today authorised the Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants). It is the first direct-to-consumer test to report on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in people of Ashkenazi (Eastern European) Jewish descent.
These three mutations, however, are not the most common BRCA1/BRCA2 mutations in the general population.
